Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365000 · ClinicalTrials.gov registry record · Phase 1
Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01365000 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 21 participants.
The verdict
NCT01365000, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.
Interventions
- DRUG NKTR118 Formulation 1
- DRUG NKTR118 Formulation 2
- DRUG NKTR118 Formulation 3
- DRUG NKTR118 Formulation 1a
- DRUG NKTR118 Formulation 3a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365000
The ClinicalTrials.gov registry entry for NCT01365000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NKTR118 Formulation 1 is the first listed.
NCT01365000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01365000 about?
NCT01365000 is a clinical study titled "Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects". The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.
What is the current status of trial NCT01365000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01365000?
The interventions under investigation include: NKTR118 Formulation 1 (DRUG), NKTR118 Formulation 2 (DRUG), NKTR118 Formulation 3 (DRUG), NKTR118 Formulation 1a (DRUG), NKTR118 Formulation 3a (DRUG).
Who is sponsoring clinical trial NCT01365000?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.